Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.56 - $1.24 $4,704 - $10,416
-8,400 Reduced 2.36%
348,061 $254,000
Q2 2021

Aug 11, 2021

BUY
$5.11 - $7.64 $33,015 - $49,362
6,461 Added 1.85%
356,461 $2.1 Million
Q1 2021

May 13, 2021

BUY
$5.03 - $10.5 $1.76 Million - $3.68 Million
350,000 New
350,000 $2.5 Million
Q1 2020

May 14, 2020

SELL
$2.3 - $5.5 $2,300 - $5,500
-1,000 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$3.0 - $5.0 $3,000 - $5,000
1,000 New
1,000 $3,000
Q3 2019

Nov 14, 2019

SELL
$3.31 - $5.6 $4,352 - $7,363
-1,315 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$5.28 - $8.2 $28,079 - $43,607
-5,318 Reduced 80.17%
1,315 $7,000
Q1 2019

May 15, 2019

SELL
$5.84 - $12.02 $1,308 - $2,692
-224 Reduced 3.27%
6,633 $52,000
Q4 2018

Feb 14, 2019

BUY
$6.32 - $19.44 $43,336 - $133,300
6,857 New
6,857 $54,000

Others Institutions Holding EQ

About Equillium, Inc.


  • Ticker EQ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,352,100
  • Market Cap $25.8M
  • Description
  • Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...
More about EQ
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.